Abstract
Here, we report that TW01001, a novel piperazinedione compound, could be a new mitotic inhibitor for the treatment of non-small cell lung cancer by the following observations in A549 cells: (1) induction of cells to accumulate at G2/M phase, which ultimately led to cell apoptotic death, (2) accumulation of p53 and inhibition of survival signalings, and (3) induction of p53-independent autophagy. Taken together, our data suggested that TW01001 induces autophagy-p53-signaling pathway to cause mitotic arrest and cell growth inhibition in A549 cells and provides the framework for further development as a novel therapeutic agent for lung cancer treatment.
Original language | English |
---|---|
Pages (from-to) | 370-378 |
Number of pages | 9 |
Journal | Cancer Letters |
Volume | 336 |
Issue number | 2 |
DOIs | |
Publication status | Published - Aug 19 2013 |
Keywords
- Apoptosis
- Autophagy
- Lung cancer
- Mitotic arrest
- Signal transduction
ASJC Scopus subject areas
- Oncology
- Cancer Research